PB2518: OPTIMIZING THE DETECTION OF 2,3- DIPHOSPHOGLYCERATE IN DRIED BLOOD SPOTS OF PATIENTS WITH SICKLE CELL DISEASE: UNTARGETED METABOLOMICS WITHIN THE GENOMED4ALL PROJECT

Ähnliche Einträge

• P-023: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
  von: VAN DER VEEN S., et al.
  Veröffentlicht: (2022-08-01)
• P1500: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
  von: S. van der Veen, et al.
  Veröffentlicht: (2022-06-01)
• P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
  von: Myrthe van Dijk, et al.
  Veröffentlicht: (2023-08-01)
• Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
  von: Myrthe J. vanDijk, et al.
  Veröffentlicht: (2024-06-01)
• Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency
  von: Birgit van Dooijeweert, et al.
  Veröffentlicht: (2020-09-01)